专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013019058A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER RECURRENCE OR METASTASIS 审中-公开
标题翻译：用于抑制癌症复发或METASTASIS的药物组合物
公开(公告)号：WO2013019058A2
公开(公告)日：2013-02-07
申请号：PCT/KR2012006096
申请日：2012-07-31
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG-WUK , MIN CHANG-HEE , KOO JA-SEONG , SUN SANG-OUK , KIM YONG-EUN
发明人： KIM SUNG-WUK , MIN CHANG-HEE , KOO JA-SEONG , SUN SANG-OUK , KIM YONG-EUN
IPC分类号： A61K31/70 , A61K31/7004 , A61P35/00
CPC分类号： A61K45/06 , A61K9/2054 , A61K31/155 , A61K31/4015 , A61K31/7004 , A61K2300/00
摘要： The present invention relates to a pharmaceutical composition for inhibiting cancer recurrence or metastasis and a method for inhibiting cancer recurrence or metastasis using the same. The present invention identified the activity of 2-deoxy-D-glucose (2-DG, below) for the inhibition of mammosphere formation and EMT, indicating its inhibitory effect against proliferation of cancer stem cell and cancer metastasis, which has not been known hitherto. The present invention also identified that the combined use of a biguanide based antidiabetic agent or its pharmaceutically acceptable salt and 2-DG can inhibit cancer metastasis and steeply decrease cancer recurrence in comparison to the single use of said active ingredients, resulting in a superior effect in the inhibition of cancer metastasis and recurrence when the same dosage is applied. Therefore, the pharmaceutical composition of the present invention can be used to show substantially more excellent effect with less amount of each active ingredient, reducing the side effects due to the use of excess drug and due to their pharmacological action, and providing more efficacious treatment. Moreover, when it is used along with an anticancer agent to which resistance is shown, it is expected that more synergistic effect can be exhibited. Therefore, the pharmaceutical composition and method for inhibiting cancer recurrence or metastasis according to the present invention can be used very advantageously for the treatment and prevention of metastasis or recurrence of various cancer diseases.
摘要翻译：本发明涉及抑制癌症复发或转移的药物组合物，以及使用该组合物抑制癌症复发或转移的方法。本发明鉴定了2-脱氧-D-葡萄糖（2-DG，以下）用于抑制乳腺球形成和EMT的活性，表明其对癌干细胞增殖的抑制作用和癌转移，迄今尚未知晓。本发明还指出，与单次使用所述活性成分相比，基于双胍类抗糖尿病药或其药学上可接受的盐和2-DG的组合使用可以抑制癌症转移并急剧降低癌症复发，导致在当施用相同的剂量时，抑制癌症转移和复发。因此，本发明的药物组合物可以用较少量的各种活性成分显示出更优异的效果，减少由于使用过量药物引起的副作用，并由于其药理作用，并提供更有效的治疗。此外，当与其所示的抗癌剂一起使用时，预期可以表现出更多的协同效应。因此，根据本发明的用于抑制癌症复发或转移的药物组合物和方法可以非常有利地用于治疗和预防各种癌症疾病的转移或复发。

2. 发明申请

WO2011159100A3 ANTI-CANCER PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：抗癌药物组合物
公开(公告)号：WO2011159100A3
公开(公告)日：2012-05-03
申请号：PCT/KR2011004382
申请日：2011-06-15
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG-WUK , JUN SUNG-SOO , MIN CHANG-HEE , KOO JA-SEONG , KIM JIN-WOOK , KIM YONG-EUN , SUN SANG-OUK
发明人： KIM SUNG-WUK , JUN SUNG-SOO , MIN CHANG-HEE , KOO JA-SEONG , KIM JIN-WOOK , KIM YONG-EUN , SUN SANG-OUK
IPC分类号： A61K31/155 , A61K31/70 , A61P35/00
CPC分类号： A61K31/155 , A61K31/7004 , A61K2300/00
摘要： The present invention relates to an anti-cancer pharmaceutical composition comprising phenformin or a pharmaceutically acceptable salt thereof and 2-deoxy-D-glucose as active ingredients, having anticancer activity. The pharmaceutical composition shows far superior anticancer effects through the synergistic action between each active ingredient over the case using a single active ingredient, and can reduce the side effects caused by drugs due to the decrease of dose. In addition, the present invention can remarkably reduce side effects such as lactic acidosis caused by phenformin through delayed release or delayed administration of active ingredients. Particularly, the pharmaceutical composition according to the present invention also has increased compliance of a patient, and thus can be very useful for treating various types of cancers.
摘要翻译：本发明涉及具有抗癌活性的包含苯乙双胍或其药学上可接受的盐和作为活性成分的2-脱氧-D-葡萄糖的抗癌药物组合物。通过使用单一活性成分的情况下的各活性成分之间的协同作用，药物组合物显示出优异的抗癌作用，并且可以减少由于剂量降低而引起的药物副作用。此外，本发明可以通过延迟释放或延迟施用活性成分显着降低由苯乙双胍引起的乳酸性酸中毒的副作用。特别地，根据本发明的药物组合物也具有增加患者的依从性，因此可以非常适用于治疗各种类型的癌症。

3. 发明申请

WO2011028016A3 PHARMACEUTICAL PREPARATION COMPRISING BETA-ADRENERGIC BLOCKERS AND ANGIOTENSIN II RECEPTOR BLOCKERS 审中-公开
标题翻译：包含β-亚单位阻滞剂和血管紧张素II受体阻断剂的药物制备
公开(公告)号：WO2011028016A3
公开(公告)日：2011-07-14
申请号：PCT/KR2010005918
申请日：2010-09-01
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , LEE NAYOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , LEE NAYOUNG
IPC分类号： A61K9/24 , A61K9/52 , A61K47/38 , A61P9/12
CPC分类号： A61K9/1652 , A61K9/2846 , A61K9/4808
摘要： The present invention relates to a pharmaceutical preparation comprising: an immediate-release compartment including beta-adrenergic blockers as pharmacologically active ingredients; and an extended-release compartment including angiotensin II receptor blockers as pharmacologically active ingredients. The preparation of the present invention exhibits uniform anti-tension effects and effects of preventing complications, and particularly, maintains the blood pressure at a constant level in the dangerous time period in which complications might occur, and thus can be effectively used for a hypertension patient suffering from complications and for a patient requiring the blood pressure thereof to be inhibited during sleep, and effectively reduces side effects caused by the interaction between drugs.
摘要翻译：本发明涉及一种药物制剂，其包含：包含β-肾上腺素能阻滞剂作为药理活性成分的速释隔室; 以及作为药理活性成分的包含血管紧张素II受体阻断剂的延长释放室。本发明的制剂具有均匀的抗张力效果和预防并发症的效果，特别是在可能发生并发症的危险时间段内将血压保持在恒定水平，因此可有效地用于高血压患者患有并发症和需要在睡眠期间抑制其血压的患者，并且有效地减少由药物之间的相互作用引起的副作用。

4. 发明申请

WO2011008054A2 BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME 审中-公开
标题翻译： N，N-二甲基间苯二甲酰胺二酰胺的丁酸盐，其制备方法以及含有该化合物的药物组合物和组合物
公开(公告)号：WO2011008054A2
公开(公告)日：2011-01-20
申请号：PCT/KR2010004674
申请日：2010-07-16
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , MIN CHANGHEE , KANG MIN SEOK , KIM YONG EUN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , MIN CHANGHEE , KANG MIN SEOK , KIM YONG EUN , KOO JA SEONG
IPC分类号： C07C279/26 , A61K31/155 , A61P3/10 , C07C53/124
CPC分类号： A61K31/155 , C07C53/124 , C07C279/26
摘要： The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.
摘要翻译：本发明提供二甲双胍丁酸盐，其制备方法，以及包含其的药物组合物和组合。根据本发明的二甲双胍丁酸盐与二甲双胍盐酸盐相比具有优异的药理学效果，并且通过施用少于盐酸二甲双胍的量能够达到治疗目的。此外，二甲双胍丁酸盐具有优异的物理化学性质，例如溶解性，稳定性，吸湿性和吸附防止性，制剂的可加工性，因此能够有效地用作二甲双胍的药学上可接受的盐。

5. 发明申请

WO2010090502A3 EXTERNAL USE COMPOSITION CONTAINING CHOLECALCIFEROL OR ITS DERIVATIVE FOR TREATING SKIN DISORDERS 审中-公开
标题翻译：含有选择素或其衍生物用于治疗皮肤病的外用组合物
公开(公告)号：WO2010090502A3
公开(公告)日：2011-01-20
申请号：PCT/KR2010000808
申请日：2010-02-09
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK
IPC分类号： A61K31/59 , A61K9/127 , A61P17/00
CPC分类号： A61K31/59 , A61K9/0014 , A61K9/127
摘要： The prevent invention relates to an external use composition containing cholecalciferol or a derivative thereof for treating skin disorders. More specifically, the present invention relates to an external preparation composition for treating skin disorders such as atopic dermatitis and a method for manufacturing a liposome. The composition and method increase skin penetration by enclosing cholecalciferol (vitamin D3) or a derivative thereof as an active ingredient in a nanoscopic liposome so that skin penetration time can be minimized when applied to a lesion. Therefore, variations in drug effects due to light are reduced and drug effects are quickly expressed.
摘要翻译：本发明涉及含有胆钙化甾醇或其衍生物用于治疗皮肤病的外用组合物。更具体地说，本发明涉及用于治疗诸如特应性皮炎的皮肤疾病的外用制剂组合物和制备脂质体的方法。组合物和方法通过将胆钙化醇（维生素D3）或其衍生物作为活性成分包封在纳米级脂质体中来增加皮肤渗透，使得当施用于病变时可以最小化皮肤穿透时间。因此，由于光引起的药物作用的变化减少，药物作用迅速表达。

6. 发明申请

WO2009134057A3 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009134057A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002225
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，并且延长释放室具有血管紧张素-II受体阻断剂作为药理学活性成分。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

7. 发明申请

WO2009125981A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125981A3
公开(公告)日：2009-12-10
申请号：PCT/KR2009001822
申请日：2009-04-08
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
IPC分类号： A61K9/22 , A61K9/48 , A61K31/165 , A61K31/41 , A61K31/4178 , A61K31/4196 , A61P9/10
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供药物制剂，其包含含有作为药理学活性成分的肾素抑制剂的隔室和具有作为药理学活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔室是立即释放隔室，另一个隔室是延长释放隔室。由于所公开的制剂在不同的时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它在减少对副作用的关注，改善药物效果和简化药物使用说明方面具有优势。此外，该配方可以在药理学，临床，科学和经济上获得比单独或一次服用这些成分的复杂处方情况在预防和治疗代谢综合征，心血管疾病和肾病中更有用的效果。

8. 发明申请

WO2009127922A2 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127922A2
公开(公告)日：2009-10-22
申请号：PCT/IB2009000331
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/44 , A61K47/38 , A61P9/00
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation containing an immediate-release compartment and an extended-release compartment. The immediate-release compartment comprises a statin lipid-lowering drug, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient and the extended-release compartment contains a dihydropyridine calcium channel blocker, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient. The combined formulation of immediate-release, statin lipid-lowering drug and extended-release dihydropyridine calcium channel blocker, is pharmacologically, clinically, scientifically, and economically more useful than the single formulation of each of the drugs or a simple combination of the drugs, in preventing and treating cardiovascular disease, cardiopulmonary disease, pulmonary disease, or kidney disease in patients with metabolic syndrome and insulin resistance and patients with diabetes or suspected prediabetes. médicamentsThe formulation of the present invention allows different release times for the statin lipid-lowering drug and the dihydropyridine calcium channel blocker, and thus prevents mutual antagonism and side effects between the two drugs, and provides easy administration for patients simultaneously taking the two drugs simultaneously.
摘要翻译：本发明提供了含有速释隔室和缓释隔室的药物制剂。速释隔室包含作为药理活性成分的他汀类降脂药，其异构体或其药学上可接受的盐，并且缓释室包含二氢吡啶类钙通道阻断剂，其异构体或其药学上可接受的盐，作为药理学有效成分。速释他汀类降脂药和缓释二氢吡啶钙通道阻滞剂的组合制剂在药理学，临床，科学和经济上比每种药物的单一制剂或药物的简单组合更有用，用于预防和治疗代谢综合征和胰岛素抵抗患者中的心血管疾病，心肺疾病，肺病或肾病以及糖尿病或怀疑前驱糖尿病患者。本发明的制剂允许他汀类降脂药和二氢吡啶类钙通道阻滞剂的释放时间不同，从而防止两种药物之间的相互拮抗和副作用，并且为同时服用两种药物的患者提供了容易的给药。

9. 发明申请

WO2009125981A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125981A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001822
申请日：2009-04-08
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
IPC分类号： A61K9/22 , A61K9/48 , A61K31/165 , A61K31/41 , A61K31/4178 , A61K31/4196 , A61P9/10
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供了包含含有作为药理活性成分的肾素抑制剂的隔室的药物制剂和具有作为药理活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔间是立即释放隔间，另一个是延长隔间。由于所公开的制剂在不同时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它有利于减少对副作用的关注，改善药物作用，并简化药物使用说明书。另外，与预防和治疗代谢综合征，心血管疾病和肾脏疾病有关的成分单独或每次立即使用的复杂处方情况下，该制剂在药理学，临床上，科学上和经济上都能获得更多的有用效果。

10. 发明申请

WO2009104916A2 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009104916A2
公开(公告)日：2009-08-27
申请号：PCT/KR2009000803
申请日：2009-02-21
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , LEE YOUNG JOO , JANG SEOK YOUNG , JO YOUNG GWAN
IPC分类号： A61K9/52
CPC分类号： A61K9/2866 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/2095 , A61K9/4808 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/00 , A61K31/22 , A61K31/366 , A61K31/405 , A61K31/47 , A61K31/505 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The invention provides a pharmaceutical formulation, which comprises a pre-release portion containing HMG-CoA (hydroxymethylglutaryl-CoA) reductase as a pharmacologically active component, and a sustained-release portion containing bis-dihydropyridine-class calcium-channel blocker as a pharmacologically active component. The formulation of the invention offers synergy effects through co-administration of the bis-dihydropyridine-class calcium-channel blocker/HMG-CoA (hydroxymethylglutaryl-CoA) reductase, and induces the time-dependent absorption, metabolism and mechanism of individual drug through the controlled release to avoid competitive antagonistic interactions between drugs, thus maximizing effects of each pharmacologically active component while minimizing side effects, for example, the risk of myopathy, and substantially increasing the compliance of patients by taking one tablet once per day.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的HMG-CoA（羟甲基戊二酰-CoA）还原酶的预释放部分和含有双 - 二氢吡啶类钙通道阻断剂作为药理活性的缓释部分零件。本发明的制剂通过双 - 二氢吡啶类钙通道阻断剂/ HMG-CoA（羟甲基戊二酰辅酶A）还原酶的共同给药提供了协同效应，并且引起了单个药物的时间依赖性吸收，代谢和机制控制释放以避免药物之间的竞争性拮抗相互作用，从而最大化每种药理活性成分的作用，同时尽量减少副作用，例如肌病的风险，并且通过每天服用一片药物来显着增加患者的依从性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式